Globe Newswire12.10.20
Axogen Inc., a global developer and marketer of innovative surgical solutions for damage or discontinuity to peripheral nerves, has appointed Paul G. Thomas to its Board of Directors. Thomas will serve on both the Governance, Nominating and Sustainability Committee and the Science and Technology Committee.
“Paul is an excellent addition to our board, as he brings more than 30 years of proven medical device and healthcare leadership experience in fast-growing biologic and pharmaceutical companies,” commented Karen Zaderej, chairman, CEO, and president. “We are excited for Paul to join our team, and we are looking forward to his informed insights as we pursue our shared goal of improving the quality of life for nerve repair patients.”
Thomas currently serves on the board of directors of Abiomed Inc. and Surgalign Spine Technologies Inc. Thomas has more than 30 years of experience in the medtech industry and currently serves as the CEO and co-founder of Prominex Inc. Thomas also served as the CEO of Roka Bioscience from 2009 to 2017. Prior to that, Thomas served as chairman and CEO of LifeCell Corporation from 1998 until it was acquired by KCI in 2008 in a transaction valued at $1.8 billion. He also held various senior positions, including president of the Pharmaceutical Products Division, during his tenure of 15 years with Ohmeda Inc.
Thomas earned his MBA from Columbia University Graduate School of Business and completed his post graduate studies in chemistry at the University of Georgia Graduate School of Arts and Science. He earned his bachelor of science degree in chemistry from St. Michael’s College.
“I look forward to working with Karen, the Board of Directors, and the Axogen team to continue helping surgeons improve quality of life for patients with nerve injuries by developing and advancing innovative nerve repair surgical solutions,” said Thomas.
Thomas replaces outgoing Board member Robert J. Rudelius, who resigned earlier this fall following 10 years of service on the company's board.
“I would like to sincerely thank Robert for his many contributions to our company over the past ten years,” commented Zaderej. “Robert has provided valuable insight and counsel to me and others within the company as we developed innovative therapies for patients suffering from the debilitating effects of nerve damage.”
“Paul is an excellent addition to our board, as he brings more than 30 years of proven medical device and healthcare leadership experience in fast-growing biologic and pharmaceutical companies,” commented Karen Zaderej, chairman, CEO, and president. “We are excited for Paul to join our team, and we are looking forward to his informed insights as we pursue our shared goal of improving the quality of life for nerve repair patients.”
Thomas currently serves on the board of directors of Abiomed Inc. and Surgalign Spine Technologies Inc. Thomas has more than 30 years of experience in the medtech industry and currently serves as the CEO and co-founder of Prominex Inc. Thomas also served as the CEO of Roka Bioscience from 2009 to 2017. Prior to that, Thomas served as chairman and CEO of LifeCell Corporation from 1998 until it was acquired by KCI in 2008 in a transaction valued at $1.8 billion. He also held various senior positions, including president of the Pharmaceutical Products Division, during his tenure of 15 years with Ohmeda Inc.
Thomas earned his MBA from Columbia University Graduate School of Business and completed his post graduate studies in chemistry at the University of Georgia Graduate School of Arts and Science. He earned his bachelor of science degree in chemistry from St. Michael’s College.
“I look forward to working with Karen, the Board of Directors, and the Axogen team to continue helping surgeons improve quality of life for patients with nerve injuries by developing and advancing innovative nerve repair surgical solutions,” said Thomas.
Thomas replaces outgoing Board member Robert J. Rudelius, who resigned earlier this fall following 10 years of service on the company's board.
“I would like to sincerely thank Robert for his many contributions to our company over the past ten years,” commented Zaderej. “Robert has provided valuable insight and counsel to me and others within the company as we developed innovative therapies for patients suffering from the debilitating effects of nerve damage.”